Lanzhou Foci Pharmaceutical Co.Ltd(002644)
2020 Annual Report
Updated in March 2022
Section I important tips, contents and definitions
The board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee that the contents of the annual report are true, accurate and complete without false records, misleading statements or major omissions, and bear individual and joint legal liabilities.
Shi Aiguo, the person in charge of the company, Yao Yilei, the person in charge of accounting, and Xu xiankai, the person in charge of the accounting organization (Accounting Supervisor), declare that they guarantee the authenticity, accuracy and completeness of the financial report in this annual report.
All the reports of the board of directors have been considered.
This annual report involves forward-looking statements such as future plans and does not constitute the company’s substantive commitment to investors. Investors are reminded to pay attention to investment risks.
The company has analyzed the risk factors and countermeasures that the company may face in its future development in “section IV discussion and analysis of operation” of this report. Please pay attention to them.
The company’s profit distribution plan reviewed and approved by the board of directors is: Based on 510657000, distribute cash dividends of 1.20 yuan (including tax) to all shareholders for every 10 shares, send bonus shares of 0 shares (including tax), and do not use the accumulation fund to increase the share capital.
Lanzhou Foci Pharmaceutical Co.Ltd(002644) WeChat official account
catalogue
Section I important tips, contents and definitions Section 2 company profile and main financial indicators Section III business summary of the company Section IV discussion and analysis of business situation Section V important matters Section VI changes in shares and shareholders Section VII preferred shares Section 8 convertible corporate bonds Section IX directors, supervisors, senior managers and employees Section 10 corporate governance 54 section 11 relevant information of corporate bonds Section XII financial report Section 13 list of documents for future reference one hundred and forty-four
interpretation
Explanatory item refers to the explanatory content
Company / the company refers to Lanzhou Foci Pharmaceutical Co.Ltd(002644)
The articles of association refers to Lanzhou Foci Pharmaceutical Co.Ltd(002644) articles of association
Company Law refers to the company law of the people’s Republic of China and its amendments
“Securities Law” refers to the securities law of the people’s Republic of China and its amendments
Reporting period / current reporting period refers to 2020
Lanzhou New Area Project / new area project refers to the project of Lanzhou New Area Lanzhou Foci Pharmaceutical Co.Ltd(002644) science and Technology Industrial Park
Fuci group refers to Lanzhou Fuci Pharmaceutical Industry Development Group Co., Ltd
Health industry company refers to Lanzhou Fuci Health Industry Co., Ltd
Chinese herbal medicine management company refers to Gansu foci Chinese Herbal Medicine Management Co., Ltd
Fat Chi Medical Company Limited
Fuci Scientific Innovation Co., Ltd. refers to Lanzhou Fuci Scientific Innovation Co., Ltd
Fuci HongRi pharmaceutical Source Co., Ltd. refers to Gansu Fuci HongRi pharmaceutical source industry sales Co., Ltd
Fuci Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) company refers to Gansu Fuci Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) Co., Ltd
Pharmaceutical industry development company refers to Gansu foci Pharmaceutical Industry Development Co., Ltd
Fuci International Business Co., Ltd. refers to Lanzhou Fuci International Business Co., Ltd
Fuci Medical Technology Co., Ltd. refers to Lanzhou Fuci Medical Technology Co., Ltd
Shanghai foci health Co., Ltd. refers to Shanghai foci Health Technology Co., Ltd
RMB / 10000 yuan / 100 million yuan refers to RMB / 10000 yuan / 100 million yuan
Section II Company Profile and main financial indicators
1、 Company information
Stock abbreviation Lanzhou Foci Pharmaceutical Co.Ltd(002644) stock code Lanzhou Foci Pharmaceutical Co.Ltd(002644)
Shenzhen Stock Exchange
Chinese name of the company Lanzhou Foci Pharmaceutical Co.Ltd(002644)
Chinese abbreviation of the company Lanzhou Foci Pharmaceutical Co.Ltd(002644)
Foreign language name of the company (if any) Lanzhou foci Pharmaceutical Co., Ltd
The abbreviation of the company’s foreign name (if any) foci pharmaceutical
The legal representative of the company is Shi Aiguo
Registered address: No. 2289, Huashan Road, Lanzhou New Area, Lanzhou City, Gansu Province
Postal code of registered address 730000
Office address: No. 2289, Huashan Road, Lanzhou New Area, Lanzhou City, Gansu Province
Postal code of office address 730000
Company website: www.fczy.com com.
E-mail [email protected].
2、 Contact person and contact information
Secretary of the board of directors and securities affairs representative
Name: Li Baojun an Wenting
Contact address: No. 2289, Huashan Road, Lanzhou New Area, Lanzhou City, Gansu Province
Tel: 09318362318
Fax: 09318368945
E-mail [email protected]. [email protected].
3、 Information disclosure and preparation location
The name of the information disclosure media selected by the company is China Securities Journal and Securities Daily
The website of the website designated by the CSRC for publishing the annual report is www.cn info. com. cn.
The company’s annual report is prepared at the office of the board of directors
4、 Registration changes
Organization Code: 91620 Guangdong Golden Dragon Development Inc(000712) 762468n (Unified Social Credit Code)
Whether the changes of the company’s main business (if any) have changed since its listing
There is no change in the previous changes of controlling shareholders (if any)
5、 Other relevant information: accounting firm employed by the company
Name of accounting firm Dahua accounting firm (special general partnership)
Office address of the accounting firm: 1101, building 7, yard 16, Middle West Fourth Ring Road, Haidian District, Beijing
Name of signature accountant: Hui Quanhong, Xun Ying
Recommendation agencies hired by the company to perform continuous supervision duties during the reporting period □ applicable √ not applicable to financial consultants hired by the company to perform continuous supervision duties during the reporting period □ applicable √ not applicable VI. major accounting data and financial indicators whether the company needs to retroactively adjust or restate the accounting data of previous years □ yes √ no
20202019 year-on-year increase or decrease in 2018
Operating income (yuan): 6680510139262881516407 6.24% 54458104624
Net profit attributable to shareholders of the listed company (yuan) 108017966917110701882 51.91% 7291822916
Non recurring deduction attributable to shareholders of listed companies
Net profit from profit and loss (yuan): 1316714656 -621996539 311.69% 4748609913
Net cash flow from operating activities (yuan) 62888162804782298537 31.50% 3666311205
Basic earnings per share (yuan / share) 0.2115 0.139251.94% 0.1428
Diluted earnings per share (yuan / share) 0.2115 0.139251.94% 0.1428
Weighted average return on net assets 6.98%, 4.95%, 2.03%, 5.21%
At the end of 2020 and 2019, the year-end is increased or decreased compared with the end of the previous year, and at the end of 2018
Total assets (yuan) 238718179219240068696623 – 0.56% 252400117854
Net assets attributable to shareholders of listed companies (yuan): 158209069992150489636862 5.13% 144042789080
The company’s net profit before and after deducting non recurring profit and loss in the last three fiscal years is negative, and the audit report of the last year shows that the company’s continuous operation ability is uncertain □ yes √ No. the net profit before and after deducting non recurring profit and loss is negative □ yes √ no
7、 Differences in accounting data under domestic and foreign accounting standards 1. Differences in net profit and net assets in financial reports disclosed in accordance with international accounting standards and Chinese accounting standards □ applicable √ not applicable. There is no difference in net profit and net assets in financial reports disclosed in accordance with international accounting standards and Chinese accounting standards in the reporting period of the company.
2. At the same time, the difference between the net profit and net assets in the financial report disclosed in accordance with the overseas accounting standards and the Chinese accounting standards □ applicable √ not applicable. There is no difference between the net profit and net assets in the financial report disclosed in accordance with the overseas accounting standards and the Chinese accounting standards in the reporting period. 8、 Quarterly main financial indicators
Unit: Yuan
first quarter
